Internal Medicine, Rheumatology · Coon Rapids, MN
NPI
1790738185
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
9055 Springbrook Dr NW
Coon Rapids, MN, 55433
Phone (763) 780-9155
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
1,464 services
Medicare patients, 2024
251
Average age 72
Drug cost, 2024
$7.6M
3,324 prescriptions
Company payments, 2024
$16.87
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mayra G Oberto-Medina was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 318 times for 200 patients. In total Mayra G Oberto-Medina billed 1,464 services in 43 codes, and Medicare paid $51K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-10-20.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 318 | 200 | $12.20 | $3,880 |
| 99214 Office E&M - Established | Office | 315 | 181 | $68.58 | $22K |
| 36415 Venipuncture Blood Collection | Office | 279 | 140 | $8.56 | $2,389 |
| 99204 Office E&M - New | Office | 47 | 47 | $82.53 | $3,879 |
| 99215 Office E&M - Established | Office | 44 | 34 | $106.20 | $4,673 |
| 77080 Standard X-ray | Office | 33 | 33 | $29.41 | $971 |
| 99443 Telephone Services | Office | 27 | 17 | $63.95 | $1,727 |
| 73130 X-ray - Upper Extremity | Office | 24 | 12 | $22.52 | $540 |
| 99205 Office E&M - New | Office | 19 | 19 | $135.70 | $2,578 |
By year: 2022 $321K for 25,761 services; 2023 $90K for 7,260 services; 2024 $51K for 1,464 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 279 | 140 | $8.56 | $2,389 |
Medicare prescription drug claims, 2024
In 2024, the drug Mayra G Oberto-Medina prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 449 prescriptions and refills. In total Mayra G Oberto-Medina wrote 3,324 Medicare prescriptions that cost $7.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 449 | 1,097 | 154 | $15K |
| Hydroxychloroquine Sulfate Generic | 401 | 1,082 | 155 | $18K |
| Gabapentin Generic | 210 | 452 | 84 | $3,572 |
| Alendronate Sodium Generic | 192 | 489 | 75 | $2,460 |
| Prednisone Generic | 150 | 263 | 81 | $1,173 |
| Leflunomide Generic | 133 | 346 | 51 | $8,536 |
| Allopurinol Generic | 122 | 323 | 49 | $1,905 |
| Humira(Cf) Pen Adalimumab | 120 | 138 | 18 | $977K |
| Teriparatide Generic | 117 | 117 | 16 | $280K |
| Rinvoq Upadacitinib | 94 | 101 | 14 | $626K |
| Forteo Teriparatide | 94 | 150 | 22 | $615K |
| Actemra Actpen Tocilizumab | 84 | 100 | 13 | $443K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 79 | 111 | 13 | $692K |
| Kevzara Sarilumab | 76 | 89 | 14 | $363K |
| Duloxetine Hcl Generic | 55 | 144 | 16 | $1,392 |
Brand drugs: 1,071 claims; generic drugs: 2,147 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Mayra G Oberto-Medina $16.87 ($16.87 in general payments such as food, travel and fees) from 1 company. The largest payer was Orthofix Medical, Inc. with $16.87.
| Company | Payments | Amount |
|---|---|---|
| Orthofix Medical, Inc. OFIX | 1 | $16.87 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.